Doris Chen

Doris Chen is an accomplished professional in the biopharmaceutical industry with extensive experience in process development, drug substance manufacturing, and quality operations. Currently serving as Director of Process Development at Stemline Therapeutics, Inc. since August 2017, Doris has previously held significant roles, including Director of Drug Substance Manufacturing at Relypsa and Director of Quality Operations at Keryx Biopharmaceuticals. Doris's career at Bristol-Myers Squibb spanned over two decades, during which roles included Associate Director of Enzymatic Process Development Operations and Associate Director of Separation Engineering Technologies, among others. Doris Chen holds a Master of Science in Chemical Engineering from the University at Buffalo and a Bachelor of Science in Chemistry from Stony Brook University.